# NCT05157776 (NCT05157776)

> A Phase III Trial of Neoadjuvant Sintilimab and Chemotherapy for NSCLC Harboring No Driver Mutations

No report yet. It can be ordered.

- Drugs tested: sintilimab
- Indication: resectable locally advanced NSCLC harboring no driver mutations

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT05157776
- Phase: PHASE3
- Status: UNKNOWN
- Sponsor: Tongji University
- Conditions: NSCLC, Stage IIIA; EGF-R Negative Non-Small Cell Lung Cancer; ALK Negative NSCLC
- Interventions: PD-1 and chemotherapy
- Enrollment: 72
- Primary outcome: Pathologically complete response (pCR) rate

## Indexed commentary on NCT05157776 so far

Podcasts, YouTube videos and posts on X and Bluesky we have indexed that name the trial. LinkedIn posts are read for reports and the Enterprise MCP, not yet for this index. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.

- 3 posts on X

## Order

Focused, $750 at most (a smaller delivered size costs its own price): https://www.erudio.com/contact?report=nct05157776
